Answers are grounded in this paper and cite their sources.
Long‐chain polyunsaturated fatty acids (LCPUFAs) modulate therapeutic efficacy of various tumors. Omega‐3 LCPUFAs were reported to synergize with radiotherapy on non‐small cell lung cancer (NSCLC). However, the specific components and functional mechanisms of LCPUFA oxidative metabolites remain to be investigated. This study aimed to validate the relationship of LCPUFAs and their oxylipins with NSCLC radiosensitivity and to clarify the underlying mechanisms of their impacts. Liquid chromatography‐tandem mass spectrometry was used to assess the plasma concentrations of LCPUFA and their oxylipins in 39 adults with NSCLC and 44 healthy controls (HCs). Higher ω‐3 LCPUFA plasma levels were measured in the radiosensitive versus radioresistant adults with NSCLC (OR: 2.34, 95% CI [1.42, 3.86], p < 0.001; OR: 0.28, 95% CI [0.15, 0.51], p < 0.001), while 16 differential oxylipins were screened out (VIP > 1, p < 0.05 and FC > 1.5 or < 0.667). After cross analysis with the 33 LCPUFA metabolites differentially measured between the NSCLC and HC groups, five lipoxygenase products from ω‐3 LCPUFAs significantly different in the adults with NSCLC were higher in the radiosensitive group. These oxylipins reduced NSCLC cell viability in a dose‐dependent manner, and among them 16‐hydroxydocosahexaenoic acid (HDHA) substantially promoted NSCLC cell radiosensitivity. Further research indicated that 16‐HDHA enhanced irradiation‐induced DNA damage and apoptosis and inhibited NSCLC cell proliferation and migration through peroxisome proliferator‐activated receptor (PPAR) γ signaling pathway.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: